RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
妇科癌症中的细胞免疫治疗
英文原题：Cell-based immunotherapies in gynecologic cancers.
查看英文原题
Cell-based immunotherapies in gynecologic cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究思路按摘要原文分段
目的
本综述提供了妇科癌症中细胞免疫治疗最新进展的更新。
结果
嵌合抗原受体（CAR）技术已取得重大进展，如今不仅可以将CAR表达于T细胞，还可以表达于其他免疫效应细胞，如NK 细胞和巨噬细胞。基于细胞的疫苗已在临床试验中开始显示出有希望的结果。总结：妇科癌症中的基于细胞的免疫疗法持续发展，在部分患者中显示出有希望的临床疗效。
展开英文摘要原文
PURPOSE OF REVIEW: This review provides an update on recent developments in cell-based immunotherapy in gynecologic cancers. RECENT FINDINGS: Chimeric antigen receptor (CAR) technology has made significant progress allowing now for not only expressing CARs on T-cells, but also on other immune effector cells, such as natural killer cells and macrophages.
Cell-based vaccines have started to show promising results in clinical trials. SUMMARY: Cell-based immunotherapies in gynecologic cancers continue to evolve with promising clinical efficacy in select patients.
论文信息
- 作者
- Lang SM、Dorigo O
- 第一作者单位
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford School of Medicine, Stanford Cancer Institute, Stanford, California, USA.United States
- 文献类型
- 综述
- 期刊
- Current opinion in obstetrics & gynecology2022 Feb 1
- 原文标识
- PubMed 34967809 · DOI 10.1097/GCO.0000000000000760